FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367555238> ?p ?o ?g. }

• W4367555238 abstract "Background Chromosomal instability (CIN) is a cancer hallmark and it is difficult to directly measure its phenotype, while a CIN25 gene signature was established to do so in several cancer types. However, it is currently unclear whether there exists this signature in clear cell renal cell carcinoma (ccRCC), and if so, which biological and clinical implications it has. Methods Transcriptomic profiling was performed on 10 ccRCC tumors and matched renal non-tumorous tissues (NTs) for CIN25 signature analyses. TCGA and E-MBAT1980 ccRCC cohorts were analyzed for the presence of CIN25 signature, CIN25 score-based ccRCC classification, and association with molecular alterations and overall or progression-free survival (OS or PFS). IMmotion150 and 151 cohorts of ccRCC patients treated with Sunitinib were analyzed for the CIN25 impact on Sunitinib response and survival. Results The transcriptomic analysis of 10 patient samples showed robustly upregulated expression of the CIN25 signature genes in ccRCC tumors, which were further confirmed in TCGA and E-MBAT1980 ccRCC cohorts. Based on their expression heterogeneity, ccRCC tumors were categorized into CIN25-C1 (low) and C2 (high) subtypes. The CIN25-C2 subtype was associated with significantly shorter patient OS and PFS, and characterized by increased telomerase activity, proliferation, stemness and EMT. The CIN25 signature reflects not only a CIN phenotype, but also levels of the whole genomic instability including mutation burden, microsatellite instability and homologous recombination deficiency (HRD). Importantly, the CIN25 score was significantly associated with Sunitinib response and survival. In IMmotion151 cohort, patients in the CIN25-C1 group exhibited 2-fold higher remission rate than those in the CIN25-C2 group ( P = 0.0004) and median PFS in these two groups was 11.2 and 5.6 months, respectively ( P = 7.78E-08). Similar results were obtained from the IMmotion150 cohort analysis. Higher EZH2 expression and poor angiogenesis, well characterized factors leading to Sunitinib resistance, were enriched in the CIN25-C2 tumors. Conclusion The CIN25 signature identified in ccRCC serves as a biomarker for CIN and other genome instability phenotypes and predicts patient outcomes and response to Sunitinib treatment. A PCR quantification is enough for the CIN25-based ccRCC classification, which holds great promises in clinical routine application." @default.
• W4367555238 created "2023-05-01" @default.
• W4367555238 creator A5030675655 @default.
• W4367555238 creator A5033411376 @default.
• W4367555238 creator A5037677450 @default.
• W4367555238 creator A5057660178 @default.
• W4367555238 creator A5063481044 @default.
• W4367555238 creator A5066921931 @default.
• W4367555238 creator A5080981195 @default.
• W4367555238 creator A5084078831 @default.
• W4367555238 creator A5091589432 @default.
• W4367555238 date "2023-05-01" @default.
• W4367555238 modified "2023-09-30" @default.
• W4367555238 title "The chromosomal instability 25 gene signature is identified in clear cell renal cell carcinoma and serves as a predictor for survival and Sunitinib response" @default.
• W4367555238 cites W1509042831 @default.
• W4367555238 cites W2002246796 @default.
• W4367555238 cites W2007495351 @default.
• W4367555238 cites W2009427752 @default.
• W4367555238 cites W2036802367 @default.
• W4367555238 cites W2096172976 @default.
• W4367555238 cites W2097177355 @default.
• W4367555238 cites W2119113195 @default.
• W4367555238 cites W2122018421 @default.
• W4367555238 cites W2222086386 @default.
• W4367555238 cites W2335012284 @default.
• W4367555238 cites W2571183003 @default.
• W4367555238 cites W2581179619 @default.
• W4367555238 cites W2594729513 @default.
• W4367555238 cites W2761437070 @default.
• W4367555238 cites W2783667606 @default.
• W4367555238 cites W2785570233 @default.
• W4367555238 cites W2797542577 @default.
• W4367555238 cites W2805302875 @default.
• W4367555238 cites W2891405227 @default.
• W4367555238 cites W2898835023 @default.
• W4367555238 cites W2910857268 @default.
• W4367555238 cites W2943887705 @default.
• W4367555238 cites W2949747078 @default.
• W4367555238 cites W2962043899 @default.
• W4367555238 cites W2969541398 @default.
• W4367555238 cites W2999041256 @default.
• W4367555238 cites W2999417355 @default.
• W4367555238 cites W3010381821 @default.
• W4367555238 cites W3012675542 @default.
• W4367555238 cites W3029490475 @default.
• W4367555238 cites W3096713247 @default.
• W4367555238 cites W3134509668 @default.
• W4367555238 cites W3168603322 @default.
• W4367555238 cites W3204399561 @default.
• W4367555238 cites W4200098699 @default.
• W4367555238 cites W4210427248 @default.
• W4367555238 cites W4220722543 @default.
• W4367555238 cites W4229056634 @default.
• W4367555238 cites W4280567160 @default.
• W4367555238 cites W4293776708 @default.
• W4367555238 cites W4294628123 @default.
• W4367555238 cites W4297384261 @default.
• W4367555238 cites W4306174824 @default.
• W4367555238 cites W4307273994 @default.
• W4367555238 cites W4307680811 @default.
• W4367555238 doi "https://doi.org/10.3389/fonc.2023.1133902" @default.
• W4367555238 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37197417" @default.
• W4367555238 hasPublicationYear "2023" @default.
• W4367555238 type Work @default.
• W4367555238 citedByCount "0" @default.
• W4367555238 crossrefType "journal-article" @default.
• W4367555238 hasAuthorship W4367555238A5030675655 @default.
• W4367555238 hasAuthorship W4367555238A5033411376 @default.
• W4367555238 hasAuthorship W4367555238A5037677450 @default.
• W4367555238 hasAuthorship W4367555238A5057660178 @default.
• W4367555238 hasAuthorship W4367555238A5063481044 @default.
• W4367555238 hasAuthorship W4367555238A5066921931 @default.
• W4367555238 hasAuthorship W4367555238A5080981195 @default.
• W4367555238 hasAuthorship W4367555238A5084078831 @default.
• W4367555238 hasAuthorship W4367555238A5091589432 @default.
• W4367555238 hasBestOaLocation W43675552381 @default.
• W4367555238 hasConcept C104317684 @default.
• W4367555238 hasConcept C121608353 @default.
• W4367555238 hasConcept C126322002 @default.
• W4367555238 hasConcept C143998085 @default.
• W4367555238 hasConcept C150194340 @default.
• W4367555238 hasConcept C162317418 @default.
• W4367555238 hasConcept C180754005 @default.
• W4367555238 hasConcept C18431079 @default.
• W4367555238 hasConcept C2777472916 @default.
• W4367555238 hasConcept C2779490328 @default.
• W4367555238 hasConcept C2779733811 @default.
• W4367555238 hasConcept C2779767149 @default.
• W4367555238 hasConcept C2781278892 @default.
• W4367555238 hasConcept C502942594 @default.
• W4367555238 hasConcept C54355233 @default.
• W4367555238 hasConcept C61320498 @default.
• W4367555238 hasConcept C71924100 @default.
• W4367555238 hasConcept C86803240 @default.
• W4367555238 hasConceptScore W4367555238C104317684 @default.
• W4367555238 hasConceptScore W4367555238C121608353 @default.
• W4367555238 hasConceptScore W4367555238C126322002 @default.
• W4367555238 hasConceptScore W4367555238C143998085 @default.
• W4367555238 hasConceptScore W4367555238C150194340 @default.
• W4367555238 hasConceptScore W4367555238C162317418 @default.

• next